PTC Therapeutics Inc. (PTCT)

35.86
2.60 7.90
NASDAQ : Health Technology
Prev Close 33.24
Open 35.00
Day Low/High 33.31 / 38.33
52 Wk Low/High 14.56 / 52.95
Volume 6.26M
Avg Volume 833.90K
Exchange NASDAQ
Shares Outstanding 46.45M
Market Cap 2.22B
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries

The Dow and S&P 500 declined Monday as investors react to last week's escalation in the ongoing trade war between Washington and Beijing.

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

Updated interim data from a study of risdiplam were presented June 16 at the 22nd Annual SMA Researcher Meeting.

Updated Preliminary Data From SMA FIREFISH Program In Type 1 Babies Presented At The CureSMA Conference

Updated Preliminary Data From SMA FIREFISH Program In Type 1 Babies Presented At The CureSMA Conference

- risdiplam (RG7916) is well tolerated at all dose levels with no drug-related safety findings -

CHMP Adopts Positive Opinion For The Expansion Of The Translarna™ (ataluren) Label To Include Patients As Young As 2 Years Of Age

CHMP Adopts Positive Opinion For The Expansion Of The Translarna™ (ataluren) Label To Include Patients As Young As 2 Years Of Age

- European Commission ratification anticipated in coming months -

July 13th Options Now Available For PTC Therapeutics (PTCT)

Investors in PTC Therapeutics Inc saw new options become available today, for the July 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new July 13th contracts and identified one put and one call contract of particular interest.

Notice To Current PTC Stockholders: Rosen Law Firm Announces Preliminary Approval Of Derivative Settlement On Behalf Of PTC Therapeutics, Inc.

Notice To Current PTC Stockholders: Rosen Law Firm Announces Preliminary Approval Of Derivative Settlement On Behalf Of PTC Therapeutics, Inc.

On April 17, 2018, PTC Therapeutics, Inc. (NASDAQGS:PTCT) ("PTC" or the "Company"), in its capacity as a nominal defendant, entered into a Stipulation of Settlement (the "Stipulation") in the above-captioned shareholder derivative action -- in which three...

FIREFISH Transitions Into Pivotal Phase

FIREFISH Transitions Into Pivotal Phase

- First patient dosed in Type 1 Spinal Muscular Atrophy Program -

PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

- Grant Proposals from Nonprofit Patient Advocacy Organizations Due April 30, 2018

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.

Notable Monday Option Activity: PTCT, OLN, ICPT

Notable Monday Option Activity: PTCT, OLN, ICPT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PTC Therapeutics Inc , where a total of 3,147 contracts have traded so far, representing approximately 314,700 underlying shares. That amounts to about 46.8% of PTCT's average daily trading volume over the past month of 672,560 shares.

Notable Monday Option Activity: PTCT, DG, IDCC

Notable Monday Option Activity: PTCT, DG, IDCC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 6,631 contracts has been traded thus far today, a contract volume which is representative of approximately 663,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 75.2% of PTCT's average daily trading volume over the past month, of 882,305 shares.

Short Interest Increases 19% For PTCT

Short Interest Increases 19% For PTCT

The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 1,353,958 share increase in total short interest for PTC Therapeutics Inc , to 8,436,994, an increase of 19.12% since 09/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Noteworthy Wednesday Option Activity: PTCT, SNX, UPL

Noteworthy Wednesday Option Activity: PTCT, SNX, UPL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 4,409 contracts has been traded thus far today, a contract volume which is representative of approximately 440,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 69.6% of PTCT's average daily trading volume over the past month, of 633,365 shares.

TheStreet Quant Rating: D (Sell)